JP2022511194A5 - - Google Patents

Info

Publication number
JP2022511194A5
JP2022511194A5 JP2020568453A JP2020568453A JP2022511194A5 JP 2022511194 A5 JP2022511194 A5 JP 2022511194A5 JP 2020568453 A JP2020568453 A JP 2020568453A JP 2020568453 A JP2020568453 A JP 2020568453A JP 2022511194 A5 JP2022511194 A5 JP 2022511194A5
Authority
JP
Japan
Prior art keywords
product according
pharmaceutical product
trazipitant
effective amount
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020568453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511194A (ja
JP7468964B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053107 external-priority patent/WO2020069092A1/en
Publication of JP2022511194A publication Critical patent/JP2022511194A/ja
Publication of JP2022511194A5 publication Critical patent/JP2022511194A5/ja
Application granted granted Critical
Publication of JP7468964B2 publication Critical patent/JP7468964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020568453A 2018-09-28 2019-09-26 動揺病におけるトラジピタントの使用 Active JP7468964B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737992P 2018-09-28 2018-09-28
US62/737,992 2018-09-28
US201962874927P 2019-07-16 2019-07-16
US62/874,927 2019-07-16
PCT/US2019/053107 WO2020069092A1 (en) 2018-09-28 2019-09-26 Use of tradipitant in motion sickness

Publications (3)

Publication Number Publication Date
JP2022511194A JP2022511194A (ja) 2022-01-31
JP2022511194A5 true JP2022511194A5 (https=) 2022-10-05
JP7468964B2 JP7468964B2 (ja) 2024-04-16

Family

ID=68165866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568453A Active JP7468964B2 (ja) 2018-09-28 2019-09-26 動揺病におけるトラジピタントの使用

Country Status (20)

Country Link
US (2) US20220249444A1 (https=)
EP (2) EP3856338B1 (https=)
JP (1) JP7468964B2 (https=)
KR (2) KR102863233B1 (https=)
CN (1) CN111918701B (https=)
AU (1) AU2019348001B2 (https=)
BR (1) BR112020015484A2 (https=)
CA (1) CA3089238A1 (https=)
CL (1) CL2020002165A1 (https=)
DK (1) DK3856338T3 (https=)
ES (1) ES3010832T3 (https=)
FI (1) FI3856338T3 (https=)
HR (1) HRP20250097T1 (https=)
HU (1) HUE070000T2 (https=)
IL (1) IL281569B2 (https=)
MX (1) MX2020008456A (https=)
PT (1) PT3856338T (https=)
SI (1) SI3856338T1 (https=)
WO (1) WO2020069092A1 (https=)
ZA (1) ZA202004594B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) * 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
BRPI0415010B8 (pt) * 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
EP2722045B1 (en) * 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法

Similar Documents

Publication Publication Date Title
JP2022511194A5 (https=)
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
JP2018520189A5 (https=)
Ghajar et al. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial
JP2025510295A5 (https=)
JP2018507243A5 (https=)
JP2017510607A5 (https=)
JP6735020B2 (ja) アマンタジン組成物を投与する方法
FI3856338T3 (fi) Tradipitantin käyttö matkapahoinvoinnissa
JP2015522077A5 (https=)
JP2016505050A5 (https=)
JP6830156B2 (ja) メラトニンミニタブレットおよびその製造方法
US10357492B2 (en) Levosimendan for use in the treatment of motor neuron diseases (E.G. ALS)
JP2022504435A5 (https=)
JP2021530568A5 (https=)
JP2017511307A5 (https=)
Shrewsbury et al. Drug delivery via the upper nasal space: A novel route for anesthesiologists, intensivists and emergency department physicians?
CN108371712B (zh) 咖啡因与PPARγ激动剂联合制备AD药物中的用途
RU2021110930A (ru) Применение традипитанта от укачивания
JP2023539847A5 (https=)
Miller Use of levamisole in recurrent aphthous stomatitis
RU2468813C1 (ru) Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения
RU2498797C2 (ru) Комбинированное средство для лечения гриппа и орви
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
WO2024217522A1 (zh) 一种异噻唑并[5,4-d]嘧啶类化合物治疗炎性疾病的用途